Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.